3rdITACA National Congress, Milan, Italy, March 14-16, 2024.
Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks Presenter: Mauro Cancian, M.D., Ph.D. Format: Poster Presentation Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial Presenter: Giuseppe Spadaro, M.D., Ph.D. Format: Poster Presentation Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema Presenter: Andrea Zanichelli, M.D., Ph.D. Format: Pster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries Presenter: Andrea Zanichelli, M.D., Ph.D. Format: Poster Presentation Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial Presenter: Mauro Cancian, M.D., Ph.D. Format: Selected Oral and Poster Presentation Date, time: Saturday, March 16, 10:00 a.m. CET (5:00 a.m. EDT)
2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design Presenter: Anete Grumach, M.D., Ph.D. Format: Poster Presentation Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial Presenter: Markus Magerl, M.D. Format: Poster Presentation Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks Presenter: Marcus Maurer, M.D. Format: Poster Presentation Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial Presenter: Marc A. Riedl, M.D., M.S. Format: Oral Presentation Date, time: Saturday, March 16, 9:30 a.m. EDT
Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey Presenter: William Lumry, M.D. Format: Oral Presentation Date, time: Saturday, March 16, 11:15 a.m. EDT
About Pharvaris Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
Contact Maggie Beller Executive Director, Head of External and Internal Communications [email protected]